메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Oh Joo Hyun (Department of Medicine Samsung Medical Center Sungkyunkwan University School of Medicine Seoul KoreaDepartment of Medicine Nowon Eulji Medical Center Eulji University School of Medicine Seoul Korea) Jang Yeon Sil (Department of Medicine Samsung Medical Center Sungkyunkwan University School of Medicine Seoul Korea) Kang Danbee (Department of Clinical Research Design and Evaluation Samsung Advanced Institute for Health Science and Technology (SAIHST) Sungkyunkwan University School of Medicine Seoul KoreaCenter for Clinical Ep) Kim Hong Seog (Youdam Co. Ltd. Cheonan Korea) Kim Eui-Joong (Genofocus Inc. Daejeon Korea) Park So-Young (Laboratory of Pharmacognosy College of Pharmacy Dankook University Cheonan KoreaDepartment of Animal Resources Science College of Biotechnology and Bioengineering Dankook University Cheonan Korea) Kim Cheol-Hyun (Department of Animal Resources Science College of Biotechnology and Bioengineering Dankook University Cheonan Korea) Min Yang Won (Department of Medicine Samsung Medical Center Sungkyunkwan University School of Medicine Seoul Korea) Chang Dong Kyung (Department of Medicine Samsung Medical Center Sungkyunkwan University School of Medicine Seoul Korea)
저널정보
거트앤리버 발행위원회 Gut and Liver Gut and Liver 제17권 제1호
발행연도
2023.1
수록면
100 - 107 (8page)
DOI
10.5009/gnl210478

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background/Aims: There is increasing evidence that supplementation with pre- and probiotics appears to have positive effects on irritable bowel syndrome (IBS). The aim of this study was to determine the effects of a new synbiotic formulation on gastrointestinal symptoms in elderly patients with IBS. Methods: Sixty-seven IBS patients aged ≥60 years were randomly assigned to either a placebo group (n=34) or a synbiotic group (n=33). During a 4-week intervention, subjects used a placebo or a synbiotic containing Lactobacillus paracasei DKGF1 and extracts of Opuntia humifusa once a day. Patients were evaluated with the subject global assessment, visual analog scale, and Bristol stool chart. The primary outcome was the overall responder rate and the secondary outcome was the responder rates for abdominal symptom reduction at week 4. Results: Overall, responder rates were significantly higher in the synbiotic group (51.5%) than in the placebo group (23.5%) (p=0.017). Abdominal pain (58.8% vs 81.8%) and psychological well-being (26.4% vs 60.6%) were noticeably improved in the synbiotic group (p=0.038 and p=0.004, respectively). However, there were no significant differences in gas and bloating symptoms (p=0.88 and p=0.88, respectively). In patients with constipation-dominant and diarrhea-dominant IBS (n=16), the synbiotic significantly improved abdominal pain and defecation symptoms (responder rates for the placebo vs the synbiotic: 22.2% vs 85.7%, p=0.04). There were no adverse events in either group. Conclusions: The results indicate that this new synbiotic supplement can potentially relieve abdominal symptoms in elderly IBS patients.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0